The identification of EGFR-activating mutations as predictive biomarkers for first-generation EGFR tyrosine kinase inhibitors (TKIs) has ushered in a new age of precision oncology for the treatment of advanced EGFR-mutated NSCLC (Chalmers et al., 2019; Liang et al., 2019; Wang et al., 2019). Here, EGFR is linked to non-small cell lung carcinoma.